David A. Scott

发表

The NASA DAACs Support Earth Science Users' Data Needs

Kirsten A. Morris, David A. Scott, Jonathan P. Brennan, 2006 .

Flexible Parametric Illness-Death Models

Paul C. Lambert, David A. Scott, Sally R. Hinchliffe, 2013 .

Ejector applications in refrigeration and heating: An overview of modelling, operation and recent developments

David A. Scott, Zine Aidoun, Daniel Giguère, 2013 .

Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.

David A. Scott, P. Lyne, L. Drew, 2009, Bioorganic & medicinal chemistry letters.

AWARD NUMBER: W81XWH-16-1-0106 TITLE: Fragment-Based Approaches to Enhance GTP Competitive KRAS G12C Inhibitors PRINCIPAL INVESTIGATOR: Kenneth Westover CONTRACTING ORGANIZATION: University of Texas Southwestern Medical Center

David A. Scott, Kwok-Kin Wong, N. Gray, 2018 .

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

David A. Scott, Anna M. Schmoker, P. Jänne, 2022, Nature Communications.

Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507.

David A. Scott, D. Valle, L. Drew, 2013, Bioorganic & medicinal chemistry letters.

Peptide-based covalent inhibitors of MALT1 paracaspase.

David A. Scott, Hao Wu, N. Gray, 2019, Bioorganic & medicinal chemistry letters.

Discovery of a Series of Benzopyrimidodiazepinone TNK2 Inhibitors via Scaffold Morphing.

David A. Scott, N. Gray, F. Féru, 2020, Bioorganic & medicinal chemistry letters.

Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.

David A. Scott, Edward W. Tate, J. Dry, 2018, Cancer research.

Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.

David A. Scott, S. Kazmirski, A. Ferguson, 2015, Bioorganic & medicinal chemistry letters.

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.

David A. Scott, P. Jänne, N. Gray, 2022, Bioorganic & medicinal chemistry letters.

Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.

David A. Scott, A. Bass, N. Gray, 2020, ACS medicinal chemistry letters.

Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.

David A. Scott, Audrey M Davies, M. Zinda, 2009, Bioorganic & medicinal chemistry letters.

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.

David A. Scott, Bin Wang, Yongxin Han, 2008, Journal of medicinal chemistry.

In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.

David A. Scott, M. Lamb, Hai‐Jun Zhang, 2011, Bioorganic & medicinal chemistry letters.

Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.

David A. Scott, P. Lyne, B. Aquila, 2008, Bioorganic & medicinal chemistry letters.

3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.

David A. Scott, L. Drew, L. Dakin, 2011, Bioorganic & medicinal chemistry letters.

Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth

David A. Scott, Hao Wu, N. Gray, 2018, The Journal of clinical investigation.

Development and Characterization of a Wee1 Kinase Degrader.

David A. Scott, P. Sorger, N. Gray, 2019, Cell chemical biology.

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.

David A. Scott, N. Gray, Mark P. Jedrychowski, 2020, Cell reports.

Defining and targeting adaptations to oncogenic KRASG12C inhibition using quantitative temporal proteomics

David A. Scott, N. Gray, Mark P. Jedrychowski, 2019, bioRxiv.

An open-source drug discovery platform enables ultra-large virtual screens

David A. Scott, Moritz Hoffmann, Konstantin Fackeldey, 2020, Nature.

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.

David A. Scott, P. Jänne, Kwok-Kin Wong, 2017, Cell chemical biology.

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

David A. Scott, P. Jänne, N. Gray, 2022, Nature Cancer.

Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.

David A. Scott, S. Kazmirski, P. Lyne, 2016, Bioorganic & medicinal chemistry letters.

Exploring Targeted Degradation Strategy for Oncogenic KRASG12C.

David A. Scott, P. Jänne, N. Gray, 2019, Cell chemical biology.

The Antimicrobial Properties of Cannabis and Cannabis-Derived Compounds and Relevance to CB2-Targeted Neurodegenerative Therapeutics

David A. Scott, Lucy J. Sloan, D. Saxena, 2022, Biomedicines.

Discovery of sterically-hindered phenol compounds with potent cytoprotective activities against ox-LDL-induced retinal pigment epithelial cell death as a potential pharmacotherapy.

David A. Scott, F. Rossato, E. Choi, 2021, Free radical biology & medicine.

3-amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile.

David A. Scott, L. Drew, L. Dakin, 2009, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors.

David A. Scott, P. Jänne, N. Gray, 2019, ACS medicinal chemistry letters.

Benzopyrimidodiazepinone inhibitors of TNK2.

David A. Scott, N. Gray, F. Féru, 2020, Bioorganic & medicinal chemistry letters.

Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment

David A. Scott, Kristen L Jones, M. Kuroda, 2021, Molecular Cancer Research.

Quinoline and thiazolopyridine allosteric inhibitors of MALT1.

David A. Scott, Hao Wu, N. Gray, 2019, Bioorganic & medicinal chemistry letters.

Aberrant CDKN1A transcriptional response associates with abnormal sensitivity to radiation treatment

David A. Scott, P. Finnon, S. Bouffler, 2008, British Journal of Cancer.

Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase.

David A. Scott, Audrey M Davies, M. Zinda, 2009, Bioorganic & medicinal chemistry letters.

Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.

David A. Scott, Bin Wang, Yongxin Han, 2008, Journal of medicinal chemistry.